Castle Bio (CSTL) Q3 2026 Earnings Call Transcript
Castle Bio (CSTL) reported Q3 2026 revenue of $102.9M, up 24% YoY, driven by 47% growth in TissueCypher test volume. Net cash from operations was $19.7M, with $278M in cash and equivalents. The company raised full-year revenue guidance to $385M-$395M, up from $365M-$375M. DecisionDx-Melanoma saw 5% YoY growth, while TissueCypher is expected to grow 50%-52% for the year.
How this was made
The 30-second read
Why it matters
The earnings release provides the first public disclosure of Q3 results and an upward revision to full‑year revenue guidance.
Market read
New earnings numbers and guidance raise are material for investors in Castle Bio and the broader diagnostic sector.
What to watch
Potential reimbursement or regulatory hurdles could temper growth despite strong volume numbers.
Background
Castle Bio (CSTL) is a molecular diagnostic company focused on oncology and dermatology tests.
Ticker impact
Castle Bio reported Q3 2026 revenue of $102.9M and raised full-year 2026 revenue guidance to $385M-$395M.
likely upward pressure as market prices in higher revenue outlook
Revenue beat and guidance increase are fresh, material information for a micro‑cap biotech.
Market effects
Strengthens outlook for molecular diagnostic sector and competitors in oncology/dermatology testing.
Positive for US biotech investors, limited broader market effect.
Minimal; primarily impacts niche diagnostic market.
Counterpoint
Guidance raise may already be priced in; execution risk remains high for test volume growth.
Key entities
- ExecutiveDerek Maetzold
Speaker on the earnings call.
- ExecutiveFrank Stokes
Speaker on the earnings call.
